These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 20891043)
1. [Efficacy of fluoroquinolones on urological infection pathogens within biofilms]. Tets VV; Artemenko NK; Zaslavskaia NV; Tets GV Urologiia; 2010; (1):13-7. PubMed ID: 20891043 [TBL] [Abstract][Full Text] [Related]
2. [Combined action of levofloxacin and DNAase on biofilms of urogenital infection pathogens]. Tets GV; Artemenko NK; Zaslavskaia NV; Tets VV Urologiia; 2012; (1):21-4. PubMed ID: 22645996 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the antibacterial activity of lomefloxacin with that of other antibiotic/chemotherapeutic agents. Cuffini AM; Tullio V; Vaiani G; Carlone NA J Chemother; 1989 Jul; 1(4 Suppl):178-81. PubMed ID: 16312358 [No Abstract] [Full Text] [Related]
4. Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis. Roveta S; Schito AM; Marchese A; Schito GC Int J Antimicrob Agents; 2007 Nov; 30(5):415-21. PubMed ID: 17768034 [TBL] [Abstract][Full Text] [Related]
5. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Fritsche TR; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. Kwon AR; Min YH; Ryu JM; Choi DR; Shim MJ; Choi EC J Antimicrob Chemother; 2006 Sep; 58(3):684-8. PubMed ID: 16873394 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan. Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808 [TBL] [Abstract][Full Text] [Related]
8. Preliminary results on the antibacterial and killing activity of lomefloxacin. Stefani S; Pellegrino MB; Mezzatesta M; Speciale AM; Caccamo F; Russo G; Nicoletti G J Chemother; 1989 Jul; 1(4 Suppl):170-2. PubMed ID: 16312355 [No Abstract] [Full Text] [Related]
9. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates. Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230 [TBL] [Abstract][Full Text] [Related]
10. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Chong Y; Yakushiji H; Ito Y; Kamimura T Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety. Foroumadi A; Ghodsi S; Emami S; Najjari S; Samadi N; Faramarzi MA; Beikmohammadi L; Shirazi FH; Shafiee A Bioorg Med Chem Lett; 2006 Jul; 16(13):3499-503. PubMed ID: 16644219 [TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of imipenem and nine other antimicrobials against recently isolated pathogens. Bonadio M; Maccanti O; Cosci S; Giordani R J Chemother; 1989 Jul; 1(4 Suppl):58-60. PubMed ID: 16312303 [No Abstract] [Full Text] [Related]
13. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria. Moros M; Coll R; Esteve M; Parés J; Xicota MA Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373 [No Abstract] [Full Text] [Related]
14. Binary and mixed population biofilms: time-lapse image analysis and disinfection with biocides. Elvers KT; Leeming K; Lappin-Scott HM J Ind Microbiol Biotechnol; 2002 Dec; 29(6):331-8. PubMed ID: 12483475 [TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511 [TBL] [Abstract][Full Text] [Related]
16. [Study of antibiotic influence on adherence capacity of gram positive and gram negative bacteria to the cellular substrate]. Balotescu C; Israil AM; Lazăr V; Cernat R; Petrache LM; Dinu C Bacteriol Virusol Parazitol Epidemiol; 2002; 47(3-4):131-5. PubMed ID: 15085601 [TBL] [Abstract][Full Text] [Related]
17. Kinetics and quantification of antibacterial effects of beta-lactams, macrolides, and quinolones against gram-positive and gram-negative RTI pathogens. Schaper KJ; Schubert S; Dalhoff A Infection; 2005 Dec; 33 Suppl 2():3-14. PubMed ID: 16518706 [TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; López F; Alvarez J; Picazo JJ; Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245 [TBL] [Abstract][Full Text] [Related]
20. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Biedenbach DJ; Moet GJ; Jones RN Diagn Microbiol Infect Dis; 2004 Sep; 50(1):59-69. PubMed ID: 15380279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]